NDA_Panos

NDA appoints Dr Panos Tsintis

pharmafile | June 22, 2010 | Appointment | Sales and Marketing NDA, appointment, sales and marketing 

European regulatory affairs consulting group NDA has appointed Dr Panos Tsintis medical advisor to NDA Regulatory Science in a move that will also see him join the company’s Advisory Board.

Managing Director of the NDA Advisory Board David Gilbert said: “Dr Tsintis brings considerable regulatory experience from his work both as a senior regulator in highly respected EU Health Authorities and also as a regulator on the international stage.

“The NDA Advisory Board presents a team approach to provide solutions for clients and Dr Tsintis is a welcome and important addition to that team. The new position of medical advisor is also an important one for the growth of NDA and for support for our 100 regulatory professionals.”

Dr Tsintis was previously head of sector, pharmacovigilance, post-authorisation safety and efficacy of medicines for human use at the European Medicines Agency and before that was responsible for pharmacovigilance for UK regulator the MHRA.

During his tenure of appointment at the EMA (2002-2008) he was involved in all post licensing activities, major variations, extensions of indications, safety referrals, and pharmacovigilance and risk management.

Dr Tsintis’ responsibilities also covered the EudraVigilance post-marketing and clinical trial modules and he was involved in the development of other databases, including EudraPharm and tracking databases in pharmacovigilance and risk management.

Related Content

FDA accepts NDA for Karuna’s schizophrenia treatment

Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its …

FDA accepts Sun Pharma’s NDA for deuruxolitinib

India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration …

Bristol Myers Squibb’s NDA accepted by FDA

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) …

Latest content